Image credit: Vieworks, CMEF 2018
On April 30th, Vieworks published its provisional financial results for Q1 2021. These show that sales grew at an explosive pace despite a tough comparable due to strong growth in Q1 2020. Group quarterly sales reached ₩42.5bn, compared with ₩36.0bn in Q1 2020, an increase of approximately +18% YoY. This growth is on top of +22% revenue growth in Q1 2020, compared with Q1 2019.
Quarterly sales growth was driven by higher sales from both the medical and industrial business units. Sales from the medical business were approximately ₩0.5bn (+1.9%) higher and sales from the industrial business were approximately ₩3.8bn (+31.9%) higher when compared with Q1 2020. Sales growth from the medical segment was driven by higher sales of radiographic flat panel detectors, partially offset by lower sales of dynamic and R/F detectors. The companies radiographic portfolio encompasses the VIVIX-S series of detectors and the dynamic portfolio encompassed the VIVIX-D series.
The Vieworks Group
| Subsidiary | Incorporation | Control |
|---|---|---|
| Vision Viewer | Hong Kong | 100% |
| Shinui Technology | China | 100% |
| New Medical Imaging | Taiwan | 70% |
| Vieworks America | USA | 100% |
| Senso Herb | Korea | 100% |
| Vieworks EU GmbH | Germany | 100% |
| Medlink Imaging LLC | USA | 100% |
| VWTK | Turkey | 100% |
| SONOTECH | Korea | 60% |
Prerequisite Market Intelligence 